Nimodipine
 | This article is a stub. |
Nimodipine, also known under the brand name nimotop,[1] is a calcium channel blocker typically used for ischemic stroke, migraine prevention and subarachnoid hemorhage.[2][3]
Evidence[edit | edit source]
Evidence for the use of nimodipine in patients with ME/CFS is extremely limited, mostly based on personal experiences rather than clinical trials, and with mixed results reported in patients.
In 1996, Dr Ellen Wiebe published case studies of two patients with ME/CFS, including a moderately ill patient who noticed improvements in fatigue, cognitive function and muscle pain after starting nimodipine.[4] In 1998, three British doctors with a special interest in ME/CFS, stated that in their experience nimodipine and other calcium channel blockers were ineffective in patients chronic fatigue syndrome.[5]
Notable studies[edit | edit source]
Articles and blogs[edit | edit source]
- 2016, NIMODIPINE use in ME/CFS: An introduction - Susan Parker
- 2014 Nimopidine use in ME/CFS: A comprehensive guide- Susan Parker
- Jan 28, 2008, Brief notes on Nimodipine and ME/CFS - M.E. Association
Learn more[edit | edit source]
- Nimodipine - drugbank.ca
- Nimodipine - drugs.com
See also[edit | edit source]
References[edit | edit source]
- ↑ "Nimotop (Nimodipine): Uses, Dosage, Side Effects, Interactions, Warning". RxList. Retrieved August 29, 2020.
- ↑ "Nimodipine". drugbank.ca. Retrieved August 28, 2020.
- ↑ "Nimodipine". Drugs.com. Retrieved August 28, 2020.
- ↑ Wiebe, E. (November 1996). "N of 1 trials. Managing patients with chronic fatigue syndrome: two case reports". Canadian Family Physician. 42: 2214–2217. ISSN 0008-350X. PMC 2146911. PMID 8939323.
- ↑ Chaudhuri, A; Behan, WMH; Behan, PO (1998). "Chronic fatigue syndrome" (PDF). Proc R Coll Physic Edinb. 28: 150–163.
